Lege Artis Medicinae

[MANAGEMENT OF LIFE-THREATENING ENDOSCOPIC THERAPY-RESISTENT OESOPHAGUS VARICEAL BLEEDING]

ERŐSS Bálint Mihály1, SZÉKELY György1, SIKET Ferenc1, LÁZÁR István2

NOVEMBER 20, 2005

Lege Artis Medicinae - 2005;15(11)

[INTRODUCTION - Liver cirrhosis has two serious consequences: hepatic failure and portal hypertension. Portal hypertension has two important clinical appearances: variceal bleeding and therapy resistant ascites. Variceal bleeding can be recurrent and resistant to endoscopic treatment. These complications can be prevented by implantation of Transjugular Intrahepatic Portosystemic Shunt (TIPS). CLINICAL CASE - A 59 year old male with cirrhosis due to hepatitis C, was hospitalized in our department in April 2004 with variceal bleeding. We tried to control the bleeding twice by band ligation, once by sclerotherapy and with the use of Sengstaken-Blakemore tube, but bleeding continued for three weeks despite the endoscopic treatment. The patient needed intensive care therapy and was treated with more than forty units of packed red cells and plasma. At that point we decided to implant a TIPS, which was carried out succesfully. After TIPS implantation no rebleeding occured and the shunt had good patency. Moderate hepatic encephalopathy was observed, which is a well known phenomenon, but it could be treated with pharmacologic therapy. CONCLUSIONS - In case of portal hypertension TIPS implantation can prevent from variceal rebleedings and may caus significant improvement in the quality of life.]

AFFILIATIONS

  1. Fôvárosi Önkormányzat, Szent János Kórház és Rendelôintézet, I. Sz. Belgyógyászati és Gasztroenterológiai Osztály
  2. Borsod-Abaúj-Zemplén Megyei Kórház és Egyetemi Oktató Kórház, Radiológiai Intézet

COMMENTS

0 comments

Further articles in this publication

Lege Artis Medicinae

[Effects of tiotropium on lung hyperinflation, dyspnoe and exercise tolerance in COPD]

NAGY László Béla

Lege Artis Medicinae

[SCREENING OF PSYCHIATRIC SIDE EFFECT OF INTERFERON THERAPY WITH QUESTIONNAIRE]

GAZDAG Gábor, SZABÓ Zsuzsa

[INTRODUCTION - Interferon therapy is an effective treatment of several oncological, hematological and viral diseases but it can precipitate serious side effects too. Among others the most frequent are the psychiatric symptoms. These symptoms are also the most frequent reasons of non-compliance and early cessation of treatment which can be avoided with rapid recognition and adequate treatment. Therefore, the early recognition of the psychiatric symptoms is of high importance. METHODS AND RESULTS - Authors report a self-administered questionnaire developed to screen the most frequent psychiatric symptoms precipitated by interferon treatment. They also present the evaluation method for the questionnaire, which makes the evaluation of the data easier for non-psychiatrist doctors as well. Between September 2004 and July 2005 all interferon treated patients who also had psychiatric consultation filled in the questionnaire. The number of patients was 26. Authors set up a decision-making algorhythm for the evaluation, so the non-psychiatrist doctors were able to judge whether a psychiatric consultation was needed as well as its urgency. With the data of 26 interferon treated patients who all went through a psychiatric consultation during a 10 months period, authors discuss their first experience, going into details in the three false positive and the two false negative cases. CONCLUSION - Authors founded the questionnaire helpful in the clinical practice and recommended the use for doctors working in general practice. They also suggest to carry it further research with more patients to strengthen the results.]

Lege Artis Medicinae

[Peptic ulcer disease - facts and questions]

WERLING Klára

Lege Artis Medicinae

[MEDICAL TREATMENT OF LOWER URINARY TRACT SYMPTOMS DUE TO BENIGN PROSTATIC HYPERPLASIA - RISK FACTORS AND SIDE-EFFECTS]

KARSZA Attila

Lege Artis Medicinae

[MERCURY I]

NAGY Viktor

All articles in the issue

Related contents

Lege Artis Medicinae

[RIFAXIMIN IN THE TREATMENT OF HEPATIC ENCEPHALOPATHY - A MULTICENTRIC STUDY]

SZALAY Ferenc, TELEGDY László, SZELI Dóra, CSÁK Tímea, FOLHOFFER Anikó, HORVÁTH Andrea, ABONYI Margit, SZABÓ Olga, RÉDEI Csaba, NEMESÁNSZKY Elemér

[INTRODUCTION - Hepatic encephalopathy is a well-known neuropsychiatric syndrome occurring in patients with either acute or chronic liver diseases. Rifaximin, a non-absorbable antibiotic is accepted for the treatment of hepatic encehalopathy. Our aim was to investigate the efficacy and the safety of rifaximin in cirrhotic patients with hepatic encephalopathy in Hungary. PATIENTS AND METHODS - 49 patients (25 male and 24 female) with hepatic encephalopathy stage I., II. and III. were involved into the study. Patients were treated with rifaximin for seven days. The daily dose was 3x400 mg in tablets. The severity of hepatic encephalopathy was characterised by hepatic encephalopathy index (HEi) calculated as a score of five parameters; mental state, asterixis, ammonia level, number connection test and critical flicker frequency. Pretreatment and postreatment HEi were compared. RESULTS - The study was completed in 46 patients. The treatment was suspended in 2 patients who died in liver failure and in one because of oesophageal variceal bleeding. The plasma ammonia level decreased from 103.7 ± 46.4 μmol/L to 67.7 ± 32.3 μmol/L (p=0,007) during the treatment. The hepatic encephalopathy index improved in 39 (85%) patients, worsened in 4 (9%) and no change was observed in 3 cases (6%). Improvement was observed in patients both with Child B and Child C stages. Loose stool in two patients and nausea in one patient were the only registered side effects. No severe adverse event related to the study medication was observed. CONCLUSIONS - Rifaximin is an effective and safe medicine for the treatment of hepatic encephalopathy.]

Lege Artis Medicinae

[Management of bleeding from oesophageal and gastric varices]

JÓZSA Andrea, SZÉKELY Iván, SIMON János, MÁHR Árpád, HORVÁTH László, HORVÁTH Andrea, FEJES Roland, SZÉKELY András, SZABÓ Tamás, MADÁCSY László

[INTRODUCTION – Variceal haemorrhage from the oesophageal or gastric wall is a major cause of death in patients with chronic liver disease. Over the past two decades many new treatment modalities have been introduced in the management of variceal bleeding, such as emergency endoscopy, band ligation and postintervention observation of the bleeding patients in subintensive care units. This study presents the results of state-of-the-art therapy applied in our department, comparing them to published data. PATIENTS AND METHODS – Clinical records of patients with variceal haemorrhage admitted to our department between January 1st 2001 and December 31st 2004 were reviewed. Six-week mortality, incidence of recurrent bleeding, transfusion requirement and length of hospital stay were the main parameters analysed. RESULTS – A total of 228 admissions (191 patients) due to variceal bleeding were recorded in the study period. Cirrhosis was of alcoholic origin in 92% of patients. Upper endoscopy was performed in 94% of patients within 4 hours and endoscopic therapy was also applied in all but 7 patients. Octreotide was administered in 4 patients, and portosystemic shunt was performed in 1 patient. Primary endoscopic haemostasis was achieved in 85% of cases, while rebleeding rate was 31%. The mean length of total hospital stay was 10.6 days, including an average of 2.6 days in subintensive care units. The mean transfusion requirement was 3.75 units of packed red cells. Six-week mortality rate was 14.9%. CONCLUSION – In comparison to international data, the six-week mortality rate among our patients was substantially lower than that in earlier reports, and nearly equals with recent leading results.]

Hungarian Radiology

[Transjugular intrahepatic portosystemic shunt implantation in a patient with severe dilatative cardiomyopathy]

SZALÁNCZY Katalin, LÁZÁR István, STEFÁN János, KALÓ Emil

[INTRODUCTION - Indications for TIPS (transjugular intrahepatic portosystemic shunt) are usually portal hypertension induced by alcoholic or viral cirrhosis. Reported patient underwent TIPS because of a rare indication where his rapidly progressing heart failure lead to rapid deterioration of the splanchnic hypertension. CASE REPORT - A 51 years old male was admitted with severe dilatative cardiomyopathy and atrial fibrillation, generalized edema refractory to conservative treatment, and rapidly worsening hepatic laboratory test results. TIPS implantation achieved improvement of all clinical signs, decreased edema and the patient could finally be discharged. CONCLUSION - TIPS can result in improved quality of life not only in primary hepatic cirrhosis but in other clinical circumstances with portal hypertension.]

Lege Artis Medicinae

[Diabetes mellitus and the liver]

BECHER Péter, PATAI Árpád, MÁJER Katalin

[In the past years, the prevention of micro- and macrovascular complications has been the main target of diabetes treatment. Its unfavourable effects on the liver have been forgotten: the accelerated progression of the liver diseaeses and the increased risk of hepatocellular carcinoma. The multimetabolic syndrome leads to non-alcoholic fatty liver diseases (steatosis, steatohepatitis, cirrhosis). On he other hand some types of liver cirrhosis (for example the common alcoholic form) are worsening the insulin resistance, so they may due to a hepatogenous diabetes mellitus, that’s treatment is different and needs more regard, than type 2 diabetes.]

Lege Artis Medicinae

[Cirrhosis and its complications: diagnostic and treatment options]

PÁR Alajos

[During the past two decades, the management of complications of cirrhosis has dramatically changed, which substantially improved the patients’ survival. The present paper provides an overview of the diagnosis, treatment and prevention of cirrhosis and its complications including portal hypertension, variceal bleeding, ascites, hepatorenal and hepatopulmonary syndromes, encephalopathy and bacterial infection. Besides noninvasive diagnostic methods, pharmacological and endoscopic treatment modalities are discussed, with emphasis of the importance of nonselective beta-blockers, vasoactive therapy, antibiotic and albumin medication. Prevention and early diagnosis of cirrhosis as well as new pharmacological agents under development presumbaly result in further development in the management of patients with advanced, chronic liver disease.]